Current research has highlighted that rates of VTE in patients with COVID-19 appear markedly increased. Indeed, the cumulative incidence of VTE is reported to be between 25% and 49% of patients with severe COVID-19 with pulmonary embolism being the most common thrombotic complication.23–25 Importantly, even with the use of VTE thromboprophylaxis, the risk of VTE appears to remain elevated.24,26 Interestingly, when compared with non-COVID ARDS, patients with COVID-19 ARDS have a substantially increased rate of pulmonary embolism diagnosis (2.1% versus 11.7%, respectively, P=0.008) and patients diagnosed with a thrombotic complication have more than a 5-fold increase in all-cause mortality.25,27 Recently, 2 autopsy series have revealed that in patients with COVID-19 who were not clinically suspected to have VTE ante mortem, deep vein thrombosis, or pulmonary embolism was a common finding at autopsy (reported in 7/12 [58%] and 11/11 [100%], respectively).28,29 Furthermore, a small study found massive pulmonary embolism to be the direct cause of death in over 30% of patients, highlighting the important interplay between COVID-19 and venous thrombosis.29